Cargando…
Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presente...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430159/ https://www.ncbi.nlm.nih.gov/pubmed/30480383 http://dx.doi.org/10.1002/psp4.12369 |
_version_ | 1783405733472108544 |
---|---|
author | Schropp, Johannes Khot, Antari Shah, Dhaval K. Koch, Gilbert |
author_facet | Schropp, Johannes Khot, Antari Shah, Dhaval K. Koch, Gilbert |
author_sort | Schropp, Johannes |
collection | PubMed |
description | Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presented a general target‐mediated drug disposition (TMDD) model for these BsAbs, which bind to two different targets on different cell membranes. The model includes four different binding events for BsAbs, turnover of the targets, and internalization of the complexes. In addition, a quasi‐equilibrium (QE) approximation with decreased number of binding parameters and, if necessary, reduced internalization parameters is presented. The model is further used to investigate the kinetics of BsAb and TC concentrations. Our analysis shows that larger doses of BsAbs may delay the build‐up of the TC. Consequently, a method to compute the optimal dosing strategy of BsAbs, which will immediately create and maintain maximal possible TC concentration, is presented. |
format | Online Article Text |
id | pubmed-6430159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64301592019-04-01 Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy Schropp, Johannes Khot, Antari Shah, Dhaval K. Koch, Gilbert CPT Pharmacometrics Syst Pharmacol Research Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presented a general target‐mediated drug disposition (TMDD) model for these BsAbs, which bind to two different targets on different cell membranes. The model includes four different binding events for BsAbs, turnover of the targets, and internalization of the complexes. In addition, a quasi‐equilibrium (QE) approximation with decreased number of binding parameters and, if necessary, reduced internalization parameters is presented. The model is further used to investigate the kinetics of BsAb and TC concentrations. Our analysis shows that larger doses of BsAbs may delay the build‐up of the TC. Consequently, a method to compute the optimal dosing strategy of BsAbs, which will immediately create and maintain maximal possible TC concentration, is presented. John Wiley and Sons Inc. 2019-01-08 2019-03 /pmc/articles/PMC6430159/ /pubmed/30480383 http://dx.doi.org/10.1002/psp4.12369 Text en © 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Schropp, Johannes Khot, Antari Shah, Dhaval K. Koch, Gilbert Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title | Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title_full | Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title_fullStr | Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title_full_unstemmed | Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title_short | Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy |
title_sort | target‐mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430159/ https://www.ncbi.nlm.nih.gov/pubmed/30480383 http://dx.doi.org/10.1002/psp4.12369 |
work_keys_str_mv | AT schroppjohannes targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy AT khotantari targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy AT shahdhavalk targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy AT kochgilbert targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy |